MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Semi-automated MRI algorithm using susceptibility weighted imaging for differentiating multiple system atrophy with parkinsonism from Parkinson Disease

    W.-W. Lee, H.-J. Kim, C.-H. Sohn, H. Park, B. Jeon (Seoul, Republic of Korea)

    Objective: To investigate the diagnostic value of semi-automated diagnostic algorithm using 3T-MR susceptibility-weighted image (SWI) for multiple system atrophy with parkinsonism (MSA-p). Background: Iron deposition…
  • 2017 International Congress

    Unusual MRI findings of the syndrome of acute bilateral basal ganglia lesions in diabetic uremia with hyperglycemia associated dyskinesia

    P.-Y. Chen, A. Gutfreund, K. Brockmann, I. Wurster, G. Eschweiler, F. Metzger, W. Maetzler, D. Berg (Taipei, Taiwan)

    Objective: To describe the unusual image findings and clinical manifestations of the syndrome of acute bilateral basal ganglia lesions in a diabetic uremic patient with…
  • 2017 International Congress

    The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

    C. Kwan, I. Frouni, V. Nafade, D. Gagnon, M.-J. Wallman, L. Sid-Otmane, M. Parent, A. Parent, C. Rouillard, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…
  • 2017 International Congress

    Cortical excitability during a movement compared with postural control task in healthy subjects

    F. Chang, P. Menon, M. VanDen Bos, M. Kiernan, S. Vucic, V. Fung (Sydney, Australia)

    Objective: To investigate cortical excitability and surround cortical inhibition during movement compared with postural control task in healthy subjects. Background: Motor control has traditionally been…
  • 2017 International Congress

    Patient-reported hallucinations and the probability of progression to dementia in Parkinson’s disease

    K.-L. Horne, D. Myall, M. MacAskill, L. Livingston, S. Grenfell, T. Melzer, T. Pitcher, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

    Objective: To evaluate the influence of neuropsychiatric symptoms in identifying Parkinson’s disease (PD) patients who will progress to dementia (PDD) in the imminent future (~4…
  • 2017 International Congress

    The value of classical cerebrospinal fluid protein ratios and peripheral inflammation in Parkinson’s disease cognitive impairment

    M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gómez, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, M. Rodríguez-Oroz (San Sebastián, Spain)

    Objective: To evaluate cerebrospinal fluid (CSF) levels of proteins associated with neuropathological inclusions and their ratios, and CSF and plasma levels of inflammatory proteins as…
  • 2017 International Congress

    Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

    L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

    Objective: We explored the use of Rivastigmine in Parkinson’s and Lewy body dementia through assessment of quantitative data obtained from a clinical database. We focussed…
  • 2017 International Congress

    Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

    J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

    Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…
  • 2017 International Congress

    Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease

    S. Lerche, I. Wurster, B. Roeben, E. Schaeffer, C. Schulte, S. Akbas, A.-K. Hauser, C. Deuschle, T. Gasser, D. Berg, K. Brockmann (Tuebingen, Germany)

    Objective: To evaluate the influence of genetic variants on phenotypic variability and disease progression in PD patients. Background: Parkinson’s disease (PD) patients show a large…
  • 2017 International Congress

    A neuronal model of PARK20 (SYNJ1 mutation) using patient derived iPSCs

    R. Masius, M. Minneboo, M. Grochowska, M. Quadri, M. Picillo, P. Barone, V. Bonifati, W. Mandemakers (Rotterdam, Netherlands)

    Objective: The SYNJ1 homozygous mutation (p.Arg258Gln) leads to juvenile Parkinsonism (PARK20). SYNJ1 plays an important role in synaptic vesicle cycling, and regulating autophagic flux. We…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley